دورية أكاديمية
أعرض في EDS

Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies.

التفاصيل البيبلوغرافية
العنوان: Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies.
المؤلفون: Diallo D; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Somboro AM; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa., Diabate S; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Baya B; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Kone A; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Sarro YS; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Kone B; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Diarra B; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Diallo S; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Diakite M; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Doumbia S; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Toloba Y; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali., Murphy RL; Institute for Global Health, Northwestern University, Chicago, IL, United States., Maiga M; University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.; Institute for Global Health, Northwestern University, Chicago, IL, United States.
المصدر: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2021 Dec 07; Vol. 11, pp. 673100. Date of Electronic Publication: 2021 Dec 07 (Print Publication: 2021).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media SA
مواضيع طبية MeSH: Gastrointestinal Microbiome* , HIV Infections*/drug therapy , Microbiota* , Pharmaceutical Preparations* , Probiotics*/therapeutic use, Antitubercular Agents/therapeutic use ; Dysbiosis/drug therapy ; Humans
مستخلص: Tuberculosis (TB) remains a major public health concern with millions of deaths every year. The overlap with HIV infections, long treatment duration, and the emergence of drug resistance are significant obstacles to the control of the disease. Indeed, the standard first-line regimen TB treatment takes at least six months and even longer for the second-line therapy, resulting in relapses, drug resistance and re-infections. Many recent reports have also shown prolonged and significant damage of the gut microbial community (dysbiosis) from anti-TB drugs that can detrimentally persist several months after the cessation of treatment and could lead to the impairment of the immune response, and thus re-infections and drug resistance. A proposed strategy for shortening the treatment duration is thus to apply corrective measures to the dysbiosis for a faster bacterial clearance and a better treatment outcome. In this review, we will study the role of the gut microbiota in both TB infection and treatment, and its potential link with treatment duration. We will also discuss, the new concept of "Host Microbiota Directed-Therapies (HMDT)" as a potential adjunctive strategy to improve the treatment effectiveness, reduce its duration and or prevent relapses. These strategies include the use of probiotics, prebiotics, gut microbiota transfer, and other strategies. Application of this innovative solution could lead to HMDT as an adjunctive tool to shorten TB treatment, which will have enormous public health impacts for the End TB Strategy worldwide.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Diallo, Somboro, Diabate, Baya, Kone, Sarro, Kone, Diarra, Diallo, Diakite, Doumbia, Toloba, Murphy and Maiga.)
References: J Formos Med Assoc. 2019 Mar;118 Suppl 1:S10-S22. (PMID: 30269936)
J Probiotics Health. 2017 Apr;5(1):. (PMID: 28638850)
Gut. 2020 Aug;69(8):1510-1519. (PMID: 32409589)
FEMS Microbiol Lett. 2012 Sep;334(1):1-15. (PMID: 22568660)
Recenti Prog Med. 2018 Jan;109(1):59-68. (PMID: 29451524)
Rev Col Bras Cir. 2017 Nov-Dec;44(6):567-573. (PMID: 29267553)
World J Gastroenterol. 2010 Jan 14;16(2):167-75. (PMID: 20066735)
J Nutr. 2017 Jul;147(7):1468S-1475S. (PMID: 28615382)
J Antibiot (Tokyo). 2013 Oct;66(10):571-91. (PMID: 24002361)
Nat Rev Immunol. 2016 May 27;16(6):341-52. (PMID: 27231050)
Nutrients. 2014 Dec 24;7(1):17-44. (PMID: 25545101)
Front Physiol. 2017 Nov 17;8:822. (PMID: 29204120)
Int J Mol Sci. 2015 Apr 02;16(4):7493-519. (PMID: 25849657)
BMJ. 2002 Jun 8;324(7350):1361. (PMID: 12052801)
J Int Soc Prev Community Dent. 2015 Mar-Apr;5(2):81-7. (PMID: 25992331)
Psychopharmacology (Berl). 2019 May;236(5):1411-1432. (PMID: 30806744)
Pediatr Gastroenterol Hepatol Nutr. 2020 Jan;23(1):1-14. (PMID: 31988871)
mBio. 2019 Jun 4;10(3):. (PMID: 31164469)
Nat Commun. 2017 Nov 15;8(1):1512. (PMID: 29142211)
Clin Microbiol Rev. 2016 Oct;29(4):915-26. (PMID: 27608937)
J Infect. 2019 Apr;78(4):317-322. (PMID: 30107196)
Br J Nutr. 1998 Aug;80 Suppl 1:S147-71. (PMID: 9849357)
BMC Immunol. 2017 Jan 6;18(1):2. (PMID: 28061847)
mBio. 2018 Sep 18;9(5):. (PMID: 30228238)
Ann Am Thorac Soc. 2017 Nov;14(Supplement_5):S326-S331. (PMID: 29161086)
PLoS Negl Trop Dis. 2020 May 13;14(5):e0008230. (PMID: 32401750)
J Bras Pneumol. 2010 Sep-Oct;36(5):626-40. (PMID: 21085830)
BMJ. 2017 Mar 15;356:j831. (PMID: 28298355)
Clin Infect Dis. 2017 Oct 30;65(10):1745-1747. (PMID: 29020210)
Cell. 2014 Mar 27;157(1):121-41. (PMID: 24679531)
F1000Res. 2019 Sep 27;8:. (PMID: 31602294)
Ann Gastroenterol. 2016 Jan-Mar;29(1):56-62. (PMID: 26752951)
Aliment Pharmacol Ther. 2015 Aug;42(4):470-6. (PMID: 26096320)
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):687-701. (PMID: 32826966)
Immunology. 2018 Jun;154(2):230-238. (PMID: 29637999)
Front Pharmacol. 2012 Sep 21;3:171. (PMID: 23049509)
Mucosal Immunol. 2020 Mar;13(2):190-204. (PMID: 31772320)
PLoS One. 2013 Dec 13;8(12):e83445. (PMID: 24349510)
Cancer Res. 2017 Apr 15;77(8):1783-1812. (PMID: 28292977)
Curr Opin Microbiol. 2017 Feb;35:8-15. (PMID: 27883933)
Nutrients. 2019 Nov 22;11(12):. (PMID: 31766592)
Gastroenterol Res Pract. 2015;2015:517597. (PMID: 26146498)
Vaccine. 2015 Apr 8;33(15):1808-14. (PMID: 25748336)
Genome Med. 2016 Apr 27;8(1):51. (PMID: 27122046)
Science. 2018 Jan 5;359(6371):97-103. (PMID: 29097493)
Front Nutr. 2021 May 07;8:626254. (PMID: 34026804)
Microbiome. 2017 Jul 7;5(1):71. (PMID: 28683818)
Genome Med. 2016 Apr 13;8(1):39. (PMID: 27074706)
PLoS One. 2010 Jan 20;5(1):e8804. (PMID: 20098711)
ISRN Nutr. 2013 Jan 02;2013:481651. (PMID: 24959545)
Cell Mol Life Sci. 2020 Apr;77(8):1497-1509. (PMID: 31729564)
Folia Microbiol (Praha). 2020 Apr;65(2):245-264. (PMID: 31773556)
BMC Infect Dis. 2016 Nov 28;16(1):714. (PMID: 27894266)
Tuberk Biolezni Legkih. 2010;(4):23-7. (PMID: 27534022)
World J Gastroenterol. 2017 May 21;23(19):3565-3568. (PMID: 28596693)
Protein Cell. 2018 May;9(5):432-445. (PMID: 29705929)
J Thorac Dis. 2019 Oct;11(Suppl 17):S2173-S2180. (PMID: 31737344)
J Immunol Res. 2019 Apr 16;2019:1603758. (PMID: 31143780)
Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502. (PMID: 28611480)
Sci Rep. 2017 Sep 7;7(1):10767. (PMID: 28883399)
EBioMedicine. 2021 Jun;68:103435. (PMID: 34139429)
Microbiome. 2020 Jun 30;8(1):103. (PMID: 32605663)
Nat Rev Rheumatol. 2020 May;16(5):282-292. (PMID: 32157196)
Clin Infect Dis. 2021 Jun 1;72(11):1919-1926. (PMID: 32333760)
Pharm Res. 2016 Jun;33(6):1486-96. (PMID: 26928668)
PLoS One. 2013 Jun 11;8(6):e64898. (PMID: 23776440)
Am J Rhinol Allergy. 2016 Nov 1;30(6):202-205. (PMID: 28124641)
Hum Microb J. 2020 Mar;15:None. (PMID: 34435164)
JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1114-1121. (PMID: 25917895)
Immunology. 2018 Jun;154(2):220-229. (PMID: 29569377)
Sci Rep. 2017 Jul 6;7(1):4753. (PMID: 28684845)
Indian J Microbiol. 2018 Mar;58(1):123-125. (PMID: 29434408)
Front Immunol. 2018 Apr 10;9:709. (PMID: 29692778)
Eur J Immunol. 2020 Dec;50(12):1976-1987. (PMID: 32673409)
Genes Dev. 2016 Jul 15;30(14):1589-97. (PMID: 27474437)
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. (PMID: 24912386)
Front Microbiol. 2015 Jul 14;6:685. (PMID: 26236287)
Clin Nutr. 2014 Oct;33(5):761-7. (PMID: 24200199)
معلومات مُعتمدة: D43 TW010350 United States TW FIC NIH HHS; R21 AI148033 United States AI NIAID NIH HHS; D43 TW010543 United States TW FIC NIH HHS
فهرسة مساهمة: Keywords: TB treatment; dysbiosis; gut microbiota; host directed-therapies; tuberculosis
المشرفين على المادة: 0 (Antitubercular Agents)
0 (Pharmaceutical Preparations)
تواريخ الأحداث: Date Created: 20211224 Date Completed: 20220127 Latest Revision: 20220127
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8688706
DOI: 10.3389/fcimb.2021.673100
PMID: 34950603
قاعدة البيانات: MEDLINE
الوصف
تدمد:2235-2988
DOI:10.3389/fcimb.2021.673100